Evidence map›Paper›PMID 34847866›Full record

ArticleBMC cancer2021

pERK-mediated IL8 secretion can enhance the migration, invasion, and cisplatin resistance of CD10-positive oral cancer cells.

Yinfei Pu, Qingxiang Li, Yifei Wang, Le Xu, Qiao Qiao, Yuxing Guo, Chuanbin Guo

Open access · goldAbstract read
In one paragraph

Article in BMC cancer, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.1field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 13 citations in OpenAlex.

  1. Review
  2. Review
  3. Tumor-associated macrophages drive heterogenetic CD10International journal of biological sciences · 2025
    Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Blockade of store-operated calcium entry sensitizes breast cancer cells to cisplatin therapy via modulating inflammatory response.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2023
    Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 2 countries.

Yinfei Pu *Department of Oral and Maxillofacial Surgery, Peking University School and Hospital of Stomatology, NO. 22, Zhongguancun South Street, Haidian District, Beijing, 100081, China.
Qingxiang Li *Department of Oral and Maxillofacial Surgery, Peking University School and Hospital of Stomatology, NO. 22, Zhongguancun South Street, Haidian District, Beijing, 100081, China.
Yifei WangDepartment of Oral and Maxillofacial Surgery, Peking University School and Hospital of Stomatology, NO. 22, Zhongguancun South Street, Haidian District, Beijing, 100081, China.
Le XuDepartment of Oral and Maxillofacial Surgery, Peking University School and Hospital of Stomatology, NO. 22, Zhongguancun South Street, Haidian District, Beijing, 100081, China.
Qiao QiaoDepartment of Oral and Maxillofacial Surgery, Peking University School and Hospital of Stomatology, NO. 22, Zhongguancun South Street, Haidian District, Beijing, 100081, China.
Yuxing GuoDepartment of Oral and Maxillofacial Surgery, Peking University School and Hospital of Stomatology, NO. 22, Zhongguancun South Street, Haidian District, Beijing, 100081, China. gladiater1984@163.com.
Chuanbin GuoDepartment of Oral and Maxillofacial Surgery, Peking University School and Hospital of Stomatology, NO. 22, Zhongguancun South Street, Haidian District, Beijing, 100081, China. guodazuo@sina.com.
National Clinical Research Center for Digestive Diseases · CNPeking University · CNStomatology Hospital · CNKing University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCancer stem cells (CSCs) drive tumor initiation and progression and participate in tumor chemoresistance. We recently discovered that oral squamous cell carcinoma (OSCC) cells that highly express CD10 (CD10H cells) present cancer stem cells (CSC)-associated characteristics, which, in turn, affect the tumor growth, epithelial-mesenchymal transition (EMT), and resistance to cisplatin. In this study, we further investigated this mechanism in vitro and in vivo. We hypothesized that IL8 might regulate migration, invasion, and cisplatin resistance of CD10-positive oral cancer cells through the ERK pathway.

methodsCD10 MicroBead Kit was used to select HN6 cells with high and low expression of CD10. The target protein IL8 was screened via protein chip assay. Lentiviral transduction and specific inhibitor were applied to investigate the signaling pathway. Real-time PCR, Western blot, and immunohistochemistry were used to analyze the mRNA and protein expression; transwell assay, spheroid formation assay, and cell viability assay were used to study the cell biological behavior in vitro; xenograft animal model was used to evaluate the tumor formation rate in vivo.

resultsOverexpression of CD10 promoted CSC-related genes expression and enhanced migration, invasion, spheroid formation, and chemoresistance in HN6 cells. Moreover, the overexpression of IL8 was detected in OSCC tumor tissue and cell lines (HN6 and CAL27) overexpressing CD10. IL8 secreted by CD10H HN6 promoted migration and invasion and restored tumor chemosensitivity via the p-ERK signaling pathway, while the inhibition of IL8 increased the chemosensitivity to cisplatin.

conclusionsIL8 secretion by CD10 positive cells promotes migration, invasion, and cisplatin resistance of OSCC via the p-ERK signaling pathway.

Indexed as

Drug Resistance, NeoplasmAnimalsAntineoplastic AgentsCell CommunicationCell MovementCisplatineIF-2 KinaseFemaleGene ExpressionHeterograftsHumansInterleukin-8MiceMice, Inbred BALB CMice, NudeMouth NeoplasmsAntineoplastic AgentsCisplatinEIF2AK3 protein, humaneIF-2 KinaseInterleukin-8NeprilysinCisplatinDrug resistanceIL8, CD10, p-ERKOral squamous cell carcinoma

Identifiers

PMID34847866
PMCPMC8638179
OpenAlexW3215524535

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.